maintain fve incyt follow solid fourth-
quarter result outlook
updat forecast estim apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim apr
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
lead drug jakafi initi gain traction
drug approv sever myelofibrosi rare blood disord
jakafi stronghold mf market like continu especi
two lead competitor drug left play field
lacklust pivot trial data expand jakafi label
polycythemia vera late steroid refractori acut graft
versu host diseas may evalu drug
essenti thrombocythemia togeth push peak
sale billion
market jak inhibitor olumi baricitinib
approv europ rheumatoid arthriti
 partner seriou infect
malign weigh compet jak inhibitor
xeljanz olumi black box label thrombocytosi
cloud launch jak like rinvoq
launch back away olumi
howev think robust late-stag pipelin focus
primarili oncolog autoimmun indic
provid attract long-term growth opportun firm
second-gener jak inhibitor itacitinib recent fail
phase data first-lin treatment acut graft versu host
diseas see strong potenti topic version activ
ingredi jakafi ruxolitinib phase trial
dermatolog indic includ atop dermat vitiligo
beyond jak inhibit receiv fda approv
pemigatinib second-lin cholangiocarcinoma patient fgfr
alter studi first-lin set well
bladder cancer tumor agnost trial remain progress
data roll begin late
once-promis inhibitor program fail
also built suit asset evalu
combin immuno-oncolog indic program
preclin phase develop expect see
initi data parsaclisib
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
focus discoveri develop small-molecul drug
firm lead drug jakafi treat two type rare blood cancer graft
versu host diseas partner novarti market
drug includ rheumatoid arthriti treatment olumi eli lilli
licens oncolog drug iclusig chronic myeloid leukemia
pipelin includ broad array oncolog autoimmun program
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
maintain fve incyt follow solid
fourth-quart result outlook feb
maintain per share fair valu estim
follow fourth-quart result includ slightli
lower oper expens assum
research
previous
incorpor jakafi sale grew almost
billion continu assum billion peak
sale drug lend support firm
narrow moat pipelin mix result
past sever month disappoint result next-
gener jak itacitinib posit data topic
ruxolitinib atop dermat promis acquisit
ex-u right morphosi lymphoma drug tafasitamab
januari lower fair valu estim follow
failur itacitinib acut graft versu host diseas
drug still trial chronic gvhd prophylaxi
reduc assum probabl approv
howev continu see promis
ruxolitinib atop dermat vitiligo ad data
quarter pivot vitiligo data like next year
model potenti billion peak sale topic
version best-sel drug addit think
gain right tafasitamab fair price
firm hematologist-focus salesforc jakafi also
serv well market new drug
receiv food drug administr approv
end year data later year first-lin
dlbcl posit could see signific upsid
current estim assum potenti sale
billion profit split morphosi
potenti combin regimen unless see evid
lower fair valu estim per
share follow failur next-gener
jak inhibitor itacitinib acut graft versu host diseas
drug still trial chronic gvhd prophylaxi
reduc assum probabl approv
olumi market eli lilli receiv
royalti percentag sale addit
develop regulatori mileston project
olumi royalti revenu near million
toward end forecast period roughli sale
optimist compani partnership
checkpoint modul program direct gitr
howev yet attribut
valu model enter early-stag
jakafi continu strong perform mf pv
lacklust pivot result gilead momelotinib
cti pharma/baxalta pacritinib believ jakafi
near-term growth prospect improv drug
signific first-mov advantag product
come market includ bristol newli approv inreb
narrow label black box warn
think approv jakafi polycythemia vera acut
gvhd potenti
essenti
thrombocythemia could lead peak sale
billion
also like launch pemigatinib patient
rare form cholangiocarcinoma also
benefit experi oncolog think
key driver remain tie ruxolitinib howev
remain cautiou effort refresh jakafi
oral ruxolitinib franchis once-daili version
valuat exclud incyt ido inhibitor program light
epacadostat phase trial failur metastat
melanoma combin merck inhibitor
keytruda anticip lacklust result remain
trial evalu epacadostat combin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
myeloprolif neoplasm mpn market
includ mf pv merit narrow econom moat rate
firm heavili depend jakafi sale nearli
revenu recent hit profit within
past year howev lack near-term threat
jakafi domin mf pv popul
incyt strong price power give us confid
compani gener return cost capit
forese futur
strong competit posit thank
jakafi franchis myeloprolif neoplasm
treatment approv food drug
administr myelofibrosi approv
polycythemia vera refractori patient drug
signific price power first-mov advantag
compet pipelin treatment jakafi solid efficaci
safeti profil patient popul high unmet
need allow compani set averag annual price
world-wide jakafi key patent expir
exclud potenti extens give incyt
signific runway build franchis expand
et gvhd indic
pipelin competit thin recent year
forese signific near-term threat
gilead drug momelotinib cti biopharma/baxalta
drug pacritinib previous led competit
acquisit impact biomedicin earli
celgen reviv anoth competitor program fedratinib
bristol receiv approv drug call inreb
august howev continu believ jakafi set
high bar first-lin treatment next round novel
molecul target myelofibrosi indic -- includ
telomeras inhibitor imetelstat exit
partnership roche/promedior
partnership
astrazeneca bristol would provid upsid fair valu
given depend hand market
drug regulatori commerci risk pipelin
believ firm warrant high uncertainti rate
bull-cas scenario assum jakafi success
expand indic see extend patent
protect key late-stag pipelin candid
higher probabl approv greater oper
leverag result per share fair valu estim
bear-cas scenario model jakafi struggl
penetr mpn market sever gener
roughli
probabl approv pipelin drug oper
cost result signific financi burden
base case result fair valu drop per
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
rheumatoid arthriti drug olumi receiv multipl
setback last fda approv mg
dose mg black box warn due concern
imbal thrombot event treatment
arm phase data upadacitinib approv
rinvoq gilead filgotinib expect
approv look efficaci olumi ra
base top-lin result jak inhibitor
xeljanz first market despit steep competit
believ ra market could support multipl oral jak
inhibitor given high patient churn therapi
potenti near-term catalyst
progress dim time believ uptak
antifibrot modul expect use
patient toler jakafi low level
platelet fail jakafi therapi near-term
prospect promis view mani early-stag
competitor trial way includ checkpoint
inhibitor keytruda opdivo howev believ
earli candid signific threat
robust pipelin mitig threat
futur jakafi sale compani sever early-
late-stag candid focus primarili oncolog
autoimmun indic incyt topic ruxolitinib
phase atop dermat vitiligo fgfr inhibitor
pemigatinib formerli inhibitor
think posit moat trend base
potenti jakafi label expans progress
compani robust early-stag pipelin jakafi carv
strong defens market posit
addit label expans pv drug achiev
blockbust statu label expans acut chronic
graft-versus-host-diseas et could boost futur
compani procur
candid immuno-oncolog target posit
well increasingli key therapeut area
compani also sever earlier-stag candid focus
primarili oncolog autoimmun indic
recent partner checkpoint modul
program direct gitr
opportun remain rel unproven incyt
healthi pipelin give firm margin error believ
strategi develop combin oncolog
regimen bode favor competit advantag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
jakafi first fda-approv treatment
rare blood disord known myelofibrosi
give strong price power market penetr
market upend monopoli
label expans
dermatolog provid near-term
catalyst firm
crowd market
thrombocytosi black box warn market
disadvantag
broad array pipelin oncolog
autoimmun program give firm larger margin
error
oth failur ido inhibitor melanoma
term asset pipelin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end billion cash
market secur limit debt balanc sheet
howev like biotechnolog compani
histor oper loss high cost
clinic trial research loss financ
larg offer equiti debt secur
collabor research develop fund arrang
develop mileston partner despit
heavi spend expect firm reach
sustain profit jakafi sale intern
royalti off-set high invest
histor post loss due heavi
research develop spend firm current
sound financi shape prolong loss eros
jakafi sale could put financi posit jeopardi
signific risk mani drug candid
never reach market jakafi phase trial failur
pancreat cancer significantli reduc
optimist predict exampl addit new
competitor jakafi could reach market erod
competit posit drug also small
molecul ensur gener competit
difficult stave goe patent melanoma
trial failur highli anticip ido inhibitor
epacadostat combin merck inhibitor
keytruda also highlight development risk associ
biotech compani furthermor baricitinib
demonstr attract profil conveni oral
formul ra market highli competit
demonstr launch pfizer xeljanz
disappoint even though first oral
product market abbvi newli approv rinvoq
could give olumi run money market
olumi approv less efficaci mg
dose amid concern thrombot event mg dose
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
hoppenot took ceo join
presid oncolog novarti believ
hoppenot experi establish pharma firm
valuabl pipelin matur firm
transit one-drug start-up matur
diversifi biopharmaceut compani given firm
lack sustain profit past focus
deploy capit research develop
result capital-alloc decis
judg manag howev believ firm
licens agreement eli lilli olumi dictat
favor term compani sharehold alik
substanti royalti mileston payment
although execut commerci
jakafi well without previou experi view
think would difficult go alon
competit rheumatoid arthriti market also like
manag strategi deploy cash gener
jakafi franchis acquir early-stag oncolog drug
ceo/chairman board/
repres date owner name posit common share held report holder issuer
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
